Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study

Acta Neuropathol Commun. 2021 Jul 19;9(1):126. doi: 10.1186/s40478-021-01226-2.

Abstract

Activation of the complement system propagates neuroinflammation and brain damage early and chronically after traumatic brain injury (TBI). The complement system is complex and comprises more than 50 components, many of which remain to be characterized in the normal and injured brain. Moreover, complement therapeutic studies have focused on a limited number of histopathological outcomes, which while informative, do not assess the effect of complement inhibition on neuroprotection and inflammation in a comprehensive manner. Using high throughput gene expression technology (NanoString), we simultaneously analyzed complement gene expression profiles with other neuroinflammatory pathway genes at different time points after TBI. We additionally assessed the effects of complement inhibition on neuropathological processes. Analyses of neuroinflammatory genes were performed at days 3, 7, and 28 post injury in male C57BL/6 mice following a controlled cortical impact injury. We also characterized the expression of 59 complement genes at similar time points, and also at 1- and 2-years post injury. Overall, TBI upregulated the expression of markers of astrogliosis, immune cell activation, and cellular stress, and downregulated the expression of neuronal and synaptic markers from day 3 through 28 post injury. Moreover, TBI upregulated gene expression across most complement activation and effector pathways, with an early emphasis on classical pathway genes and with continued upregulation of C2, C3 and C4 expression 2 years post injury. Treatment using the targeted complement inhibitor, CR2-Crry, significantly ameliorated TBI-induced transcriptomic changes at all time points. Nevertheless, some immune and synaptic genes remained dysregulated with CR2-Crry treatment, suggesting adjuvant anti-inflammatory and neurotropic therapy may confer additional neuroprotection. In addition to characterizing complement gene expression in the normal and aging brain, our results demonstrate broad and chronic dysregulation of the complement system after TBI, and strengthen the view that the complement system is an attractive target for TBI therapy.

Keywords: Complement inhibition; Complement system; Gene expression; NanoString; Neuroinflammation; Traumatic brain injury.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Brain / drug effects*
  • Brain / immunology
  • Brain / metabolism
  • Brain / pathology
  • Brain Injuries, Traumatic / genetics*
  • Brain Injuries, Traumatic / immunology
  • Brain Injuries, Traumatic / pathology
  • Brain Injury, Chronic / genetics*
  • Brain Injury, Chronic / immunology
  • Brain Injury, Chronic / pathology
  • Complement Activation / genetics*
  • Complement Activation / immunology
  • Complement C2 / genetics
  • Complement C2 / immunology
  • Complement C3 / antagonists & inhibitors
  • Complement C3 / genetics
  • Complement C3 / immunology
  • Complement C4 / genetics
  • Complement C4 / immunology
  • Complement Inactivating Agents / pharmacology
  • Gene Expression Profiling
  • Mice
  • Neuroinflammatory Diseases / genetics*
  • Neuroinflammatory Diseases / immunology
  • Recombinant Fusion Proteins / pharmacology
  • Transcriptome

Substances

  • CR2-Crry fusion protein, mouse
  • Complement C2
  • Complement C3
  • Complement C4
  • Complement Inactivating Agents
  • Recombinant Fusion Proteins